Near-infrared-actuated devices for remotely controlled drug delivery
Name
Timko-2014-Near-infrared-actuat.pdf
Size
1.29 MB
Format
Adobe PDF
Checksum (MD5)
e7e35a65ba2c7452399329016fccf4fa
Author(s)
Timko, Brian P.
Arruebo, Manuel
Shankarappa, Sahadev A.
McAlvin, J. Brian
Okonkwo, Obiajulu Stephanie
Mizrahi, Boaz
Stefanescu, Cristina F.
Gomez, Leyre
Zhu, Jia
Santamaria, Jesus
Date Issued
January 2014
Journal
Proceedings of the National Academy of Sciences
Publisher
National Academy of Sciences (U.S.)
Citation
Timko, B. P., M. Arruebo, S. A. Shankarappa, J. B. McAlvin, O. S. Okonkwo, B. Mizrahi, C. F. Stefanescu, et al. “Near-Infrared-Actuated Devices for Remotely Controlled Drug Delivery.” Proceedings of the National Academy of Sciences 111, no. 4 (January 28, 2014): 1349–1354.
Version
Final published version
Abstract
A reservoir that could be remotely triggered to release a drug would enable the patient or physician to achieve on-demand, reproducible, repeated, and tunable dosing. Such a device would allow precise adjustment of dosage to desired effect, with a consequent minimization of toxicity, and could obviate repeated drug administrations or device implantations, enhancing patient compliance. It should exhibit low off-state leakage to minimize basal effects, and tunable on-state release profiles that could be adjusted from pulsatile to sustained in real time. Despite the clear clinical need for a device that meets these criteria, none has been reported to date to our knowledge. To address this deficiency, we developed an implantable reservoir capped by a nanocomposite membrane whose permeability was modulated by irradiation with a near-infrared laser. Irradiated devices could exhibit sustained on-state drug release for at least 3 h, and could reproducibly deliver short pulses over at least 10 cycles, with an on/off ratio of 30. Devices containing aspart, a fast-acting insulin analog, could achieve glycemic control after s.c. implantation in diabetic rats, with reproducible dosing controlled by the intensity and timing of irradiation over a 2-wk period. These devices can be loaded with a wide range of drug types, and therefore represent a platform technology that might be used to address a wide variety of clinical indications.
MIT Department
Harvard University--MIT Division of Health Sciences and Technology
Massachusetts Institute of Technology. Department of Chemical Engineering
Massachusetts Institute of Technology. Department of Chemistry
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1073/pnas.1322651111
